These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 1699279)

  • 21. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic study of fludarabine phosphate (NSC 312887).
    Hersh MR; Kuhn JG; Phillips JL; Clark G; Ludden TM; Von Hoff DD
    Cancer Chemother Pharmacol; 1986; 17(3):277-80. PubMed ID: 2427240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
    Casper ES; Mittelman A; Kelson D; Young CW
    Cancer Chemother Pharmacol; 1985; 15(3):233-5. PubMed ID: 2414021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids.
    Kemena A; Fernandez M; Bauman J; Keating M; Plunkett W
    Clin Chim Acta; 1991 Aug; 200(2-3):95-106. PubMed ID: 1723357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism and therapeutic efficacy of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia P388.
    Avramis VI; Plunkett W
    Cancer Res; 1982 Jul; 42(7):2587-91. PubMed ID: 7083151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes.
    Sandoval A; Consoli U; Plunkett W
    Clin Cancer Res; 1996 Oct; 2(10):1731-41. PubMed ID: 9816124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
    Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
    Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
    J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine in mice, dogs, and monkeys.
    El Dareer SM; Struck RF; Tillery KF; Rose LM; Brockman RW; Montgomery JA; Hill DL
    Drug Metab Dispos; 1980; 8(2):60-3. PubMed ID: 6103788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics and pharmacodynamics of fludarabine in rheumatoid arthritis.
    Knebel W; Davis JC; Sanders WD; Fessler B; Yarboro C; Pucino F; Boumpas DT
    Pharmacotherapy; 1998; 18(6):1224-9. PubMed ID: 9855320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
    Brockman RW; Cheng YC; Schabel FM; Montgomery JA
    Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proposed mechanism of therapeutic selectivity for 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells.
    Barrueco JR; Jacobsen DM; Chang CH; Brockman RW; Sirotnak FM
    Cancer Res; 1987 Feb; 47(3):700-6. PubMed ID: 3802076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of fludarabine (2-fluoro-ara-AMP).
    Kavanagh JJ; Krakoff IH; Bodey GP
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1009-11. PubMed ID: 2415365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
    Huang P; Plunkett W
    Mol Pharmacol; 1991 Apr; 39(4):449-55. PubMed ID: 1708088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential arabinosylcytosin with or without fludarabine in paracmastic patients with acute myeloid leukemia.
    Liang A; Zhang H; Fang Y; Li Y; Zhu D; Chen F; Lu H; Fu J; Bo L
    Pharmazie; 2012 Jul; 67(7):635-8. PubMed ID: 22888522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.